Artelo Biosciences Presents Groundbreaking Research At Annual CBD Symposium In Canada
Portfolio Pulse from Joana Scopel
Artelo Biosciences (NASDAQ:ARTL) presented new data at the International Cannabinoid Research Society Symposium, highlighting the pharmaceutical properties and efficacy of its patented cannabidiol (CBD) cocrystal, ART12.11. The research findings demonstrate improved bioavailability and efficacy in nonclinical models of stress-induced anxiety versus CBD.
June 27, 2023 | 1:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Artelo Biosciences presented new data on its patented CBD cocrystal, ART12.11, showing improved bioavailability and efficacy in nonclinical models of stress-induced anxiety.
The new data presented by Artelo Biosciences on its patented CBD cocrystal, ART12.11, demonstrates improved pharmaceutical properties and efficacy compared to CBD alone. This could potentially lead to increased interest in the company's products and a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100